{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":39,"n_cols":5,"rows_kept":39,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[8,2,8,3],[9,2,9,3],[12,2,12,3],[12,4,12,5],[13,2,13,3],[13,4,13,5],[14,2,14,3],[14,4,14,5],[15,2,15,3],[16,2,16,3],[20,2,20,3],[21,2,21,3],[22,2,22,3],[23,2,23,3],[24,2,24,3],[26,2,26,3],[27,2,27,3],[31,2,31,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910699348203321"]
[null,null,"Titolo",null,"Narcotic drugs [[electronic resource] ] : agreement between the United States of America and Nicaragua signed at Managua June 1, 2001"]
[null,null,"Pubbl/distr/stampa",null,"[Washington, D.C.] : , : U.S. Dept. of State, , [2001?]"]
[null,null,"Descrizione fisica",null,"1 online resource (33 unnumbered pages)"]
[null,null,"Collana",null,"Treaties and other international acts series ; ; 13153"]
[null,null,"Soggetti",null,"Drug control - Nicaragua"]
[{"$nulls":4},"Drug control - United States"]
[{"$nulls":4},"Drug control - International cooperation"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Title from title screen (viewed on Jan. 28, 2010)."]
[null,"2.","Record Nr.",null,"UNINA9910813859003321"]
[null,null,"Autore",null,"Lui Kung-Jong"]
[null,null,"Titolo",null,"Binary data analysis of randomized clinical trials with noncompliance / / Kung-Jong Lui"]
[null,null,"Pubbl/distr/stampa",null,"Chichester, West Sussex, United Kingdom, : John Wiley & Sons Inc., 2011"]
[null,null,"ISBN",null,"1-283-40536-9"]
[{"$nulls":4},"9786613405364"]
[{"$nulls":4},"1-119-99160-9"]
[{"$nulls":4},"1-119-99161-7"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (332 p.)"]
[null,null,"Collana",null,"Statistics in practice"]
[null,null,"Disciplina",null,"615.5072/4"]
[null,null,"Soggetti",null,"Clinical trials - Statistical methods"]
[{"$nulls":4},"Drugs - Testing - Statistical methods"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Binary Data Analysis of Randomized Clinical Trials with Noncompliance; Contents; Preface; About the Author; 1 Randomized clinical trials with noncompliance: issues, definitions and problems of commonly used analyses; 1.1 Randomized encouragement design (RED); 1.2 Randomized consent designs; 1.2.1 Single-consent randomized design (SCRD); 1.2.2 Double-consent randomized design (DCRD); 1.3 Treatment efficacy versus programmatic effectiveness; 1.4 Definitions of commonly used terms and assumptions; 1.5 Most commonly used analyses for a RCT with noncompliance; Exercises"]
[{"$nulls":4},"2 Randomized clinical trials with noncompliance under parallel groups design 2.1 Testing superiority; 2.2 Testing noninferiority; 2.2.1 Using the difference in proportions; 2.2.2 Using the ratio of proportions; 2.2.3 Using the odds ratio of proportions; 2.3 Testing equivalence; 2.3.1 Using the difference in proportions; 2.3.2 Using the ratio of proportions; 2.3.3 Using the odds ratio of proportions; 2.4 Interval estimation; 2.4.1 Estimation of the proportion difference; 2.4.2 Estimation of the proportion ratio; 2.4.3 Estimation of the odds ratio; 2.5 Sample size determination"]
[{"$nulls":4},"2.5.1 Sample size calculation for testing superiority 2.5.2 Sample size calculation for testing noninferiority; 2.5.3 Sample size calculation for testing equivalence; 2.6 Risk model-based approach; 2.6.1 Constant "]
[{"$nulls":4},"risk additive model; 2.6.2 Constant risk multiplicative model; 2.6.3 Generalized risk additive model; 2.6.4 Generalized risk multiplicative model; Exercises; Appendix; 3 Randomized clinical trials with noncompliance in stratified sampling; 3.1 Testing superiority; 3.2 Testing noninferiority; 3.2.1 Using the difference in proportions; 3.2.2 Using the ratio of proportions"]
[{"$nulls":4},"3.2.3 Using the odds ratio of proportions 3.3 Testing equivalence; 3.3.1 Using the difference in proportions; 3.3.2 Using the ratio of proportions; 3.3.3 Using the odds ratio of proportions; 3.4 Interval estimation; 3.4.1 Estimation of the proportion difference; 3.4.2 Estimation of the proportion ratio; 3.4.3 Estimation of the odds ratio; 3.5 Test homogeneity of index in large strata; 3.5.1 Testing homogeneity of the proportion difference; 3.5.2 Testing homogeneity of the proportion ratio; 3.5.3 Test homogeneity of the odds ratio; Exercises; Appendix"]
[{"$nulls":4},"4 Randomized clinical trials with noncompliance under cluster sampling 4.1 Testing superiority; 4.2 Testing noninferiority; 4.2.1 Using the difference in proportions; 4.2.2 Using the ratio of proportions; 4.2.3 Using the odds ratio of proportions; 4.3 Testing equivalence; 4.3.1 Using the difference in proportions; 4.3.2 Using the ratio of proportions; 4.3.3 Using the odds ratio of proportions; 4.4 Interval estimation; 4.4.1 Estimation of the proportion difference; 4.4.2 Estimation of the proportion ratio; 4.4.3 Estimation of the odds ratio; 4.5 Sample size determination"]
[{"$nulls":4},"4.5.1 Sample size calculation for testing superiority"]
[null,null,null,"Sommario/riassunto","It is quite common in a randomized clinical trial (RCT) to encounter patients who do not comply with their assigned treatment. Since noncompliance often occurs non-randomly, the commonly-used approaches, including both the as-treated (AT) and as-protocol (AP) analysis, and the intent-to-treat (ITT) (or as-randomized) analysis, are all well known to possibly produce a biased inference of the treatment efficacy. This book provides a systematic and organized approach to analyzing data for RCTs with noncompliance under the most frequently-encountered situations. These include parallel sampling,"]